Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)
Hong Kong · Delayed Price · Currency is HKD 2.200
-0.070 (-3.08%)
Aug 27, 2026, 4:08 PM HKT
HKG:2185 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 38.45 | 44.93 | - | - | - | - | |
Revenue Growth | 84.29% | - | - | - | - | - |
Cost of Revenue | 23.4 | 26.92 | - | - | - | - |
Gross Profit | 15.04 | 18.02 | - | - | - | - |
Selling, General & Admin | 25.42 | 27.82 | 19.74 | 52.88 | 94.37 | 195.42 |
Research & Development | 77.62 | 61.89 | 41.3 | 111.74 | 157.83 | 214.23 |
Operating Expenses | 103.04 | 89.71 | 61.04 | 164.62 | 252.2 | 409.65 |
Operating Income | -88 | -71.69 | -61.04 | -164.62 | -252.2 | -409.65 |
Interest Expense | -7.33 | -8.74 | -0.06 | -0.58 | -0.96 | -0.69 |
Interest & Investment Income | 2.01 | 2.01 | 1.11 | 4 | 4.01 | 0.97 |
Earnings From Equity Investments | -1.21 | -1.47 | -0.99 | -1.63 | -1.43 | - |
Currency Exchange Gain (Loss) | -0.22 | -0.22 | 0.92 | 1.73 | 18.68 | -6.61 |
Other Non Operating Income (Expenses) | 11.04 | 2.36 | 0.39 | 0.91 | 1.04 | 6.15 |
EBT Excluding Unusual Items | -83.71 | -77.75 | -59.68 | -160.2 | -230.87 | -409.83 |
Gain (Loss) on Sale of Investments | -18.25 | -18.25 | -32.17 | 0.47 | - | - |
Gain (Loss) on Sale of Assets | - | - | -1.47 | -30.51 | -0 | - |
Other Unusual Items | - | - | - | 1.42 | - | - |
Pretax Income | -101.96 | -96 | -93.32 | -188.82 | -230.87 | -409.83 |
Income Tax Expense | -27.02 | -27.57 | - | - | - | - |
Earnings From Continuing Operations | -74.93 | -68.43 | -93.32 | -188.82 | -230.87 | -409.83 |
Minority Interest in Earnings | -0.57 | -1.62 | 5.38 | 12.93 | 26.63 | 48.38 |
Net Income | -75.5 | -70.05 | -87.94 | -175.89 | -204.24 | -361.45 |
Net Income to Common | -75.5 | -70.05 | -87.94 | -175.89 | -204.24 | -361.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 245 | 243 | 243 | 243 | 244 | 221 |
Shares Outstanding (Diluted) | 245 | 243 | 243 | 243 | 244 | 221 |
Shares Change | 0.79% | - | - | -0.14% | 10.50% | 61.54% |
EPS (Basic) | -0.31 | -0.29 | -0.36 | -0.72 | -0.84 | -1.64 |
EPS (Diluted) | -0.31 | -0.29 | -0.36 | -0.72 | -0.84 | -1.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -75.3 | -165.58 | -66.74 | -170.65 | -122.75 |
Free Cash Flow Per Share | - | -0.31 | -0.68 | -0.27 | -0.70 | -0.56 |
Gross Margin | 39.13% | 40.10% | - | - | - | - |
Operating Margin | -228.87% | -159.56% | - | - | - | - |
Profit Margin | -196.37% | -155.91% | - | - | - | - |
Free Cash Flow Margin | - | -167.59% | - | - | - | - |
EBITDA | -70.65 | -55.44 | -54.25 | -148.21 | -237.34 | -400.88 |
EBITDA Margin | -183.76% | -123.39% | - | - | - | - |
D&A For EBITDA | 17.34 | 16.25 | 6.79 | 16.41 | 14.87 | 8.77 |
EBIT | -88 | -71.69 | -61.04 | -164.62 | -252.2 | -409.65 |
EBIT Margin | -228.87% | -159.56% | - | - | - | - |